| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/16/2011 | EP2294428A1 A polymer adapted to release bioactive agents in vivo, pharmaceutical composition and method of preparation thereof |
| 03/16/2011 | EP2294419A1 Compostions and methods for treating corneal inflammation |
| 03/16/2011 | EP2294213A2 Methods for modulating expression of creb |
| 03/16/2011 | EP2294195A1 Oligonucleotide duplexes comprising dna-like and rna-like nucleotides and uses thereof |
| 03/16/2011 | EP2294186A2 Inducing cell death by inhibiting adaptive heat shock response |
| 03/16/2011 | EP2294077A1 Corticosteroid linked beta-agonist compounds for use in therapy |
| 03/16/2011 | EP2294072A1 Triazine compounds as p13 kinase and mtor inhibitors |
| 03/16/2011 | EP2294071A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS |
| 03/16/2011 | EP2294070A1 New phenanthrylphenol linked pyrrolo[2,l-c][l,4]benzodiazepine hybrids as potential antitumour agents and process for the preparation thereof |
| 03/16/2011 | EP2294069A1 Therapeutically useful substituted hydropyrido ý3,2,1-ij¨quinoline compounds |
| 03/16/2011 | EP2294068A1 1,3-dihydro-2h-pyrrolo[3,2-b]pyridin-2-one derivatives, preparation thereof and therapeutic uses thereof |
| 03/16/2011 | EP2294067A1 Preparation of n-6 demethylated, 9-10-dihydrolysergic acid alkyl esters |
| 03/16/2011 | EP2294066A1 Benzoimidazoles as prolyl hydroxylase inhibitors |
| 03/16/2011 | EP2294065A1 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| 03/16/2011 | EP2294063A1 Pyrrolidine ether derivatives as nk3 receptor antagonists |
| 03/16/2011 | EP2294062A1 Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof |
| 03/16/2011 | EP2294061A2 Disubstituted phthalazine hedgehog pathway antagonists |
| 03/16/2011 | EP2294057A1 PROCESS FOR PREPARING A CRYSTALLINE FORM COMPOUND OF 3-BENZYL-2-METHYL-2,3,3a,4,5,6,7,7a-OCTAHYDROBENZO[d]ISOXAZOL-4-ONE |
| 03/16/2011 | EP2294056A1 Bosentan salts |
| 03/16/2011 | EP2294055A1 Salts comprising a pyrimidinecarboxylic acid derivative for cosmetic use |
| 03/16/2011 | EP2294053A2 Glucokinase activators |
| 03/16/2011 | EP2294052A1 Process for the preparation of ezetimibe and composition containing it |
| 03/16/2011 | EP2294051A1 Alpha-substituted n-sulfonyl gylcine amides antagonists of ccr10, compositions containing the same and methods for using them |
| 03/16/2011 | EP2294050A2 Bis-aryl compounds for use as medicaments |
| 03/16/2011 | EP2294049A2 Orally active curcuminoid compounds |
| 03/16/2011 | EP2294047A2 Novel mandelate salt of fesoterodine |
| 03/16/2011 | EP2294012A1 Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
| 03/16/2011 | EP2293803A1 Immune system stimulating nutrition |
| 03/16/2011 | EP2293802A2 Lactose compositions with decreased lactose content |
| 03/16/2011 | EP2293801A1 Method for preventing corticosteroid usage |
| 03/16/2011 | EP2293800A2 Compositions and methods for treatment of ear disorders |
| 03/16/2011 | EP2293799A1 Sialic acid to support salivation |
| 03/16/2011 | EP2293798A1 Pregesteron antagonists such as cdb-4124 in the treatment of breast cancer |
| 03/16/2011 | EP2293797A1 Pregesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc |
| 03/16/2011 | EP2293795A1 Pharmaceutical combination |
| 03/16/2011 | EP2293794A1 Methods of treating mammals with eustachian tube dysfunctions |
| 03/16/2011 | EP2293793A1 2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy |
| 03/16/2011 | EP2293792A1 Diaryl ureas for treating heart failure |
| 03/16/2011 | EP2293791A1 Pharmaceutical compositions of entacapone co-micronized with sugar alcohols |
| 03/16/2011 | EP2293790A2 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders |
| 03/16/2011 | EP2293789A1 Novel depigmenting compositions in the form of a petroleum jelly-free and elastomer-free anhydrous composition comprising a solubilized phenolic derivative |
| 03/16/2011 | EP2293788A2 Novel depigmenting compositions in the form of a petroleum jelly-free and elastomer-free anhydrous composition comprising a solubilized phenolic derivative and a retinoid |
| 03/16/2011 | EP2293787A1 Nanoemulsions for treating fungal, yeast and mold infections |
| 03/16/2011 | EP2293786A2 Tablettable chewing gums comprising nicotine and a buffering agent |
| 03/16/2011 | EP2293782A2 Stable benzimidazole formulation |
| 03/16/2011 | EP2293781A1 Granulation of active pharmaceutical ingredients |
| 03/16/2011 | EP2293779A1 Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen |
| 03/16/2011 | EP2293778A2 Composition comprising an antibiotic and a corticosteroid |
| 03/16/2011 | EP2293777A1 Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
| 03/16/2011 | EP2293677A1 Nutritional composition for infants delivered via caesarean section |
| 03/16/2011 | EP2293671A1 Small molecule inhibitors for the treatment or prevention of dengue virus infection |
| 03/16/2011 | EP2293670A1 Compositions and methods for nail fungus treatment |
| 03/16/2011 | EP2293668A1 Antimicrobial compositions and methods of use |
| 03/16/2011 | EP2205575B1 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| 03/16/2011 | EP2205562B1 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives |
| 03/16/2011 | EP2173756B1 Macrolactone derivatives |
| 03/16/2011 | EP2167470B1 Triazolo [1, 5-a]quinolines as adenosine a3 receptor ligands |
| 03/16/2011 | EP2155683B1 Pyridone derivatives as p38a mapk inhibitors |
| 03/16/2011 | EP2132194B1 Substituted isoquinolines and their use as rho-kinase inhibitors |
| 03/16/2011 | EP2125786B1 Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
| 03/16/2011 | EP2111125B1 Liquid formulations comprising carotenoids |
| 03/16/2011 | EP2097453B1 Monoclonal antibodies against the human anti-müllerian hormone type ii receptor (amhr-ii) |
| 03/16/2011 | EP2094674B1 A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one |
| 03/16/2011 | EP2091939B1 Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition |
| 03/16/2011 | EP2057165B1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
| 03/16/2011 | EP2046758B1 Substituted sulphoximines as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 03/16/2011 | EP2025661B1 Fluoroalkyloxy-containing combretastatin derivatives, preparation and use thereof |
| 03/16/2011 | EP2018388B1 Bisadenosine compounds as adenosine a2a receptor agonists |
| 03/16/2011 | EP1968573B1 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder |
| 03/16/2011 | EP1940846B1 Pyrimidin-4-yl-3,4-dihydro-2h-pyrrolo[1,2a]pyrazin-1-one compounds |
| 03/16/2011 | EP1940827B1 Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 03/16/2011 | EP1879866B1 Dihydropyridine derivatives |
| 03/16/2011 | EP1879856B1 Alkyl-, alkenyl- and alkynyl carbamate derivatives, the preparation and therapeutic use thereof |
| 03/16/2011 | EP1841459B1 Use of a dihydroim1dazopyrazine derivative for treating or preventing pain |
| 03/16/2011 | EP1830850B1 Quinoline derivatives for the treatment of latent tuberculosis |
| 03/16/2011 | EP1809598B1 Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 03/16/2011 | EP1807421B1 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof |
| 03/16/2011 | EP1709193B1 Methods and materials for assessing prostate cancer therapies |
| 03/16/2011 | EP1708988B1 Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it |
| 03/16/2011 | EP1708987B1 L-(-)-moprolol l-(+)-tartrate |
| 03/16/2011 | EP1704140B1 Synthesis of optically pure (r)-5-(2-aminopropyl)-2-methoxybenzenesulphonamide |
| 03/16/2011 | EP1703906B1 Immuno inhibitory pyrazolone compounds |
| 03/16/2011 | EP1699761B1 Cb1 modulator compounds |
| 03/16/2011 | EP1648878B9 Piperidine compounds and pharmaceutical compositions containing them |
| 03/16/2011 | EP1631266B1 A method of treating degenerative disc disease |
| 03/16/2011 | EP1565239B1 Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1] nonanes for treating anti-arrhythmic events |
| 03/16/2011 | EP1513507B1 Transdermal analgesic systems with reduced abuse potential |
| 03/16/2011 | EP1495018B3 Tricyclic thrombin receptor antagonists |
| 03/16/2011 | EP1490360B1 Thiazolidinedione derivatives and pharmaceutical composition comprising the same |
| 03/16/2011 | EP1448535B1 Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 03/16/2011 | EP1420762B1 Residual solvant extraction method and microparticles produced thereby |
| 03/16/2011 | EP1417186B1 Heterocyclic aryl sulphonamides |
| 03/16/2011 | EP1351565B1 Chemical inhibitors of mismatch repair |
| 03/16/2011 | EP1344777B1 Imidazole derivatives, process for their preparation and their use |
| 03/16/2011 | CN1994290B Transdermal plaster of rivastigmine and preparation process thereof |
| 03/16/2011 | CN1994285B Sustained release micro-pellet of guaifenesin and preparation process thereof |
| 03/16/2011 | CN1972661B Use of furan alkyls for a cellulite cosmetic treatment |
| 03/16/2011 | CN1950096B Stabilizers for hydrolyzable organic binders |
| 03/16/2011 | CN1939324B Medical usage of periplocin A and E |
| 03/16/2011 | CN1917867B Compounds having antitumor activity |